Delaying Cancer Treatments and Impact on Mortality

In the unprecedented time of COVID-19, there is a dire need to understand the impact of delaying cancer treatment. A team from Canada and the United-Kingdom undertook a Systematic Review and Meta-Analysis of studies published from January 2000 to April 2020 to quantify the impact of delays in surgical interventions, systemic treatment (such as chemotherapy), or radiotherapy for seven types of cancer. These seven cancers represent “44% of all incident cancers globally”.

From analyzing studies included in the review, the authors concluded that every four-week delay in cancer treatment was associated with increased mortality. Delaying more than four weeks was associated with an even higher increase in the risk of death. For instance, delaying breast cancer surgery for eight weeks would increase the risk of death by 17%. This risk would be 26% with a twelve-week delay.

The study was published in November 2020 in the BMJ. The findings of this Systematic Review and Meta-Analysis will be instrumental in creating policies on cancer management priorities during a pandemic.

Hanna, T. P., King, W. D., Thibodeau, S., Jalink, M., Paulin, G. A., Harvey-Jones, E., O’Sullivan, D. E., Booth, C. M., Sullivan, R., & Aggarwal, A. (2020). Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ (Clinical research ed.), 371, m4087.

Disparities in Breast Cancer

October is Breast Cancer Awareness MonthOctober is Breast Cancer Awareness Month, and MSK experts have been speaking to news sources on topics related to this too-common cancer. This includes a recent piece from Today about disparities in breast cancer care for Black women.

In the United States, Black women are more likely to get diagnosed with breast cancer at a later stage and younger age than White women. They are also more likely to die from breast malignancies. MSK’s Dr. Elizabeth Comen describes how access to quality care remains inadequate for many, and how clinical trials for breast cancer treatments do not adequately represent Black patients.

Overcoming Resistance to Cancer Therapies, Nanomedicine and More

Resistance to cancer therapy is one of the most challenging problems in oncology. Two recent papers report on new findings related to the phenomena of such resistance.

  • UCSF team of researchers found that the presence of liver metastasis from any primary cancer causes resistance to immune checkpoint inhibitors therapy, specifically to anti–PD-1 immunotherapy. Using a mouse model, the scientists established a foundation for overcoming this resistance by combining anti-PD-1 with regulatory T cells targeting agents and thus restoring anti-PD-1 immunotherapy efficacy. The study was published in Science Immunology.
  • BRCA1/2 mutation-driven cancers, such as breast, ovarian, and prostate cancers, display high resistance to lifesaving therapies. Researchers from The University of Texas at Austin and Ajou University in South Korea identified a protein implicated in developing resistance to PARP inhibitors, a class of drugs that treat BRCA-deficient tumors. The study found that the low level of this protein, called PCAF, causes resistance to treatment with PARP inhibitors. The findings open the possibility of overcoming this resistance and increasing PARP inhibitors therapy’s effectiveness by combining them with a class of drugs called HDAC inhibitors, which boost PCAF. Research into PCAF protein, which has a role in chromatin modifications responsible for important DNA processes, contributes to the knowledge of cell replication and, therefore, to the understanding of disease pathophysiology. The study was published in Molecular Cell

In recent years, anti-cancer nanomedicine gained more and more ground. 

  • Researchers from two laboratories in Chicago conducted a recent study on nanotechnology that used charged nanoscale metal-organic frameworks (nMOFs) for generating free radicals using X-rays within tumor tissue to kill cancer cells directly”. “Furthermore, the same frameworks can be used for delivering immune signaling molecules known as PAMPs to activate the immune response against tumor cells. By combining these two approaches into one easily administered “vaccine,” this new technology may provide the key to better local and systemic treatment of difficult-to-treat cancers”. This study was published in Science Advances
  • Yet another study on nanotechnology took a non-conventional approach to nanoparticle use. A research team from Singapore used a silica nanoparticle as a cancer drug, instead of a conventional drug carrier. The therapeutic nanoparticle caused cancer cells to self-destruct with the same efficiency as traditional cancer drug therapy in the lab mouse experiment. The researchers also “deceived” cancer cells, notoriously dependent on amino acids for their growth, by masking the therapeutic nanoparticle with an outer layer of amino acid L-phenylalanine. This research “may hold promise for the future design of nanotherapies” and “for cancer cells that have failed to respond to conventional treatment like chemotherapy.” The study was published in Small

More studies contributing to the knowledge of cancer biology were published recently.

  • Scientists from Rockefeller University in New York found that breast and lung tumor cancer cells can use blood vessels to gain access to a signaling pathway used by neurons. The tactics ultimately enable those cancers to metastasize. This research contributes to the knowledge of how cancers use or hijack normal cells and mechanisms to progress and establishes the foundation for new diagnostic and therapeutic approaches. The study was published in Nature